[email protected]

01252 375362

01252 375362

  • About Us
    • About Pharmacy Consulting
    • Our Team
    • Work with us
    • Testimonials
  • Consultancy
    • For Pharmaceutical Wholesalers
    • For Pharmacies
    • Care Quality Commission – CQC
    • Pharmaceutical Manufacturers
    • Medical Devices Consultancy and Training
  • Flexible Training
    • Good Distribution Practice (GDP) Training
    • RPi Training
    • Licence Holder Training
    • Export Training
    • Audit Training
    • Active Pharmaceutical Ingredient (API) and Clinical Trials Training
    • Superintendent Pharmacist Training
    • GPhC Guidance for Online Pharmacies
  • RP Cogent GDP Training
  • RP Forum
  • Training Calendar
  • Our CPD
    • Blog
    • Editorial Items
    • Social Media
  • Contact Us
New Best practice guidance on the sale of medicines for pain relief

New Best practice guidance on the sale of medicines for pain relief

by Steven Hewison | Apr 2, 2025 | Blog, MHRA, Pharmacy Suppliers

The MHRA have updated their Blue Guide on Advertising and Promoting Medicines. The update is to Appendix 4 with new Best Practice guidance on the sale of medicines for pain relief.

The Windsor Framework Part 3

The Windsor Framework Part 3

by Steven Hewison | Aug 29, 2024 | Blog, MHRA, Windsor Framework

Unless they appear on the NIMAR list, PLGB licensed medicines are not licensed in Northern Ireland. That means they are effectively supplied to NI as an Unlicensed ‘Special’.

The Windsor Framework Part 3

The Windsor Framework Part 2

by Steven Hewison | Aug 28, 2024 | Blog, MHRA, Windsor Framework

After the implementation of the Windsor Framework, the Medicines and Healthcare products Regulatory Agency (MHRA) will license all medicines across the whole of the UK’.

The Windsor Framework Part 3

The Windsor Framework Part 1 (recap)

by Steven Hewison | Aug 27, 2024 | Blog, MHRA, Windsor Framework

From the 1st of January 2025 the supply of medicines to Northern Ireland will be governed by the Windsor Framework, which will replace the Northern Ireland Protocol.

Be Careful What You Advertise

Be Careful What You Advertise

by Steven Hewison | Jul 19, 2024 | Blog, MHRA, Pharmacy

Most of us will know that it is illegal to promote prescription only medicines (POMs) to members of the public, however, it is always worth a reminder that you must be careful what you advertise.

« Older Entries
Next Entries »

Recent Posts

  • FDA Warning Letters
  • Emerging issues – Communique from the GPhC
  • New MHRA/NICE Collaboration

Upcoming Courses

  • RP Forum – GxP Certificates for Customers and Supplier Qualification on 9 September 2025 10:00 am
  • Introduction to Good Distribution Practice Online Training on 10 September 2025 10:00 am
  • GDP/RP Cogent Gold Standard Online Training on 16 September 2025
  • GDP Audit Online Training on 1 October 2025 10:00 am
  • Licence Holder Training on 14 October 2025 10:00 am

MHRA Alerts & Recalls

Field Safety Notices: 11 to 15 August 2025
19 August 2025
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
14 August 2025
Field Safety Notices: 4 to 8 August 2025
12 August 2025
Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd, EL(25)A/39
7 August 2025

Get In Touch

Address:
Wellesley House
10 Eelmoor Road
Farnborough
Hampshire
GU14 7QN

Phone: 01252 375362
Email: [email protected]
  • Terms and Conditions
  • Privacy Policy

Designed by Four Lakes

  • Follow
  • Follow
  • Follow
  • Follow